News | January 09, 2012

Study Highlights Stereotactic Body Radiotherapy for Noninvasive Brachytherapy-like Treatment for Prostate Cancer

January 9, 2012 – Accuray Incorporated announced publication of a study describing the clinical outcomes of prostate cancer patients treated with stereotactic body radiotherapy (SBRT) using Accuray's CyberKnife robotic radiosurgery system in a manner that mimics high dose rate (HDR) brachytherapy dosing within the prostate gland. The University of California at San Francisco (UCSF) study, published in the January 2012 issue of the International Journal of Radiation Oncology - Biology - Physics (IJROBP - commonly known as the Red Journal), employed a radiation dose scheme following that of conventional invasive HDR brachytherapy to deliver high doses of radiation to regions of the prostate known to have a higher burden of prostate cancer cells, rather than delivering a single uniform dose to the prostate. Patients with organ confined prostate cancer were treated in four short outpatient treatment sessions. Historically, HDR brachytherapy has been shown to be an effective treatment for prostate cancer, but requires the insertion of invasive catheters into the prostate making this treatment difficult for patients and technically challenging for physicians, limiting its widespread adoption. The CyberKnife System is able to easily and quickly mimic this proven treatment in a noninvasive manner because of its ability to create and paint complex doses within the prostate.

The study, "Stereotactic Body Radiotherapy as Monotherapy or Post–External Beam Radiotherapy Boost for Prostate Cancer: Technique, Early Toxicity, and PSA Response," reported on 38 patients ranging in age from 54 to 82 years with a minimum follow-up of 12 months. Twenty of the 38 patients were treated with CyberKnife SBRT monotherapy and 18 were treated with CyberKnife SBRT boost following external beam radiotherapy (EBRT). The research found that CyberKnife SBRT was well tolerated and after a median follow-up of 18.3 months, reported progression free survival was 100 percent.

"The results are encouraging, especially when compared to historic experience for invasive HDR brachytherapy for patients with prostate cancer," said Siavash Jabbari, M.D., lead author of the study, and currently a radiation oncologist at Advocate Lutheran General Hospital, Park Ridge, Ill., "The CyberKnife System enables us to replicate HDR brachytherapy dosimetry and these early results suggest that we are able to achieve excellent clinical outcomes without the invasiveness and disadvantages of HDR brachytherapy."

Prostate SBRT is a difficult treatment that requires high degrees of accuracy and precision and the ability to actively track and correct for prostate motion during treatment. The creation of these very high dose regions (while limiting dose to organs such the urethra, bladder, and rectum) during a prostate SBRT course is enabled by the CyberKnife System's ability to sculpt dose and create complex dosing schemes to match the optimal clinical objectives for a patient. The CyberKnife System's robotic capabilities allow it to make active corrections for prostate motion during treatment, enabling clinicians to confidently deliver prostate SBRT while sparing the surrounding critical tissues.

In addition to the publication of the study in December, the second of two, multi-center Accuray sponsored CyberKnife prostate SBRT clinical studies, which focused specifically on prostate cancer patients treated with CyberKnife SBRT with HDR-like dosing, completed accrual. This multi-center prospective study involving 19 centers was led by Donald Fuller, M.D., of the CyberKnife Centers of San Diego and completed patient accrual this past month with treatment of 253 patients who are now in follow-up. This study, along with the other Accuray sponsored CyberKnife prostate SBRT multi-center study led by Swedish Cancer Center in Seattle, create the largest multi-center clinical experience for prostate SBRT to date and will serve as a strong foundation to support the long term clinical benefits and differentiation of the CyberKnife system in delivering prostate SBRT.

For more information:

Related Content

RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
Overlay Init